Charta Health’s $55M Raise Signals a Coding-Audit Shift

·

Charta Health’s $55M Raise: Audit-Proofing Codes Before Claims Go Out

On November 10, 2026, Charta Health announced a $55 million Series B, led by Insight Partners with Madrona, Bain Capital Ventures, South Park Commons, and QuantumLight also participating. The round brings the company’s total funding to $85 million across three raises in under two years, and the company says revenue grew 10x over the past 12 months. The headline number is notable on its own, but the more interesting signal for coding and compliance teams is what Charta is actually selling: a platform built to get the chart right before a claim is submitted, not to fight about it afterward.

The pitch: agree on the chart before the claim goes out

Charta’s framing, in the words of CEO Justin Liu, is that “payers and providers should agree on the chart before a claim goes out, not fight about it after.” That is a direct response to how most coding disputes actually play out today — a claim is submitted, a payer denies or down-codes it, and both sides spend weeks or months in appeals that neither wants. Charta’s AI reads clinical documentation the way a coder or auditor would, flagging codes the chart supports that were missed, and removing codes the documentation doesn’t adequately support, before the claim ever leaves the building.

On the provider side, Charta for Providers runs that review against coding guidelines, payer rules, and an organization’s own clinical protocols, with findings routed to a human coder for approval inside the EHR — a human-in-the-loop design that mirrors how most autonomous coding vendors have positioned their tools this year.

What the payer product line covers

The payer side of the business is where the compliance angle gets explicit. Charta for Payers ships as six distinct products covering retrospective HCC coding review, AI-automated second-pass coding, a first-pass smart coding platform, prospective risk adjustment intelligence, HCC validation and audit workflow tooling, and HEDIS/quality care-gap detection — in effect, a product line built around the same audit surfaces CMS and OIG scrutinize most.

Named customers include American Family Care, Grow Therapy, and Pediatric Associates Family of Companies. Grow Therapy’s Brynna Pietz is quoted saying the platform lets the company review charts at a scale that isn’t possible manually — a claim that’s become table stakes for this category of vendor, but one that’s easy to test against a payer’s own denial and audit data before buying in.

Why this lands now: audits are getting more expensive to lose

Charta’s timing tracks a broader shift in how much a bad HCC code can cost. In September 2026, HHS-OIG published two separate Medicare Advantage compliance audits finding Humana owed CMS $130.9 million and UnitedHealthcare owed $46.9 million — a combined $177.8 million in flagged overpayments, with error rates of 81% and 73% on sampled diagnosis codes, respectively (as reported by Becker’s Payer Issues). Those are recommendations, not final recoupments, and CMS still has to decide whether to pursue them — but the pattern across 2026’s OIG and DOJ activity has been consistent: diagnosis codes submitted for conditions that were resolved, not clinically supported, or not reflected in the medical record are the single most audited category in Medicare Advantage risk adjustment.

That is exactly the surface Charta’s HCC validation and audit workflow product is built to cover before CMS or OIG ever sees a claim. Whether or not Charta’s own benchmark numbers hold up at scale — the company cites a 2025 industry estimate that claims adjudication cost the system over $25 billion in 2023, with nearly $18 billion of that potentially wasted on denials and appeals, a figure Medikode has not independently verified — the direction of travel is clear: capital is moving toward pre-submission accuracy, not post-submission defense.

What it means for coding and RCM teams

For coding managers and RCM leaders, the practical takeaway isn’t “go buy Charta.” It’s that the market is validating a specific workflow change: moving coding-accuracy checks upstream of claim submission, with a human coder still signing off inside the existing EHR rather than a black-box auto-submit. Three things worth watching as this category matures:

  • Whether vendors can show audit outcomes, not just denial-rate reductions — the two aren’t the same thing, and only one of them shows up in an OIG report
  • How these tools handle the V28 HCC model’s narrower condition categories, where under-coding is now as common a finding as over-coding
  • Whether “human-in-the-loop” approval actually slows throughput enough to offset the accuracy gain, or whether it’s fast enough to keep coders in the workflow rather than around it

The caveats worth keeping in mind

It’s worth separating the funding news from the product claims. A $55 million Series B and 10x revenue growth are real signals of investor and customer demand; the specific accuracy percentages, denial-reduction figures, and market-size estimates in a funding announcement are company-reported and not independently audited. Coding and compliance teams evaluating any chart-review vendor — Charta or otherwise — should ask for audit-level outcome data tied to their own payer mix, not just a press-release benchmark.

The underlying thesis, though, doesn’t depend on any one vendor’s numbers holding up: as RADV and OIG scrutiny intensifies and extrapolated overpayment findings climb into the hundreds of millions, the cost of finding a coding error after the claim is submitted keeps rising relative to the cost of catching it before. That’s the gap Medikode’s automated medical coding platform is built to close — pairing agentic coding accuracy with the audit trail compliance and RCM teams need to defend their codes long before OIG ever asks.